GPR35 as a novel therapeutic target

Frontiers in Endocrinology

Volumn 2, Issue NOV, 2011, Pages

  MacKenzie, A E ^a   Lappin, J E ^a   Taylor, D L ^b   Nicklin, S A ^a   Milligan, G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Centre for Therapeutics Discovery   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes; G proteins; GPR35

Indexed keywords

EID: 84856841342     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00068     Document Type: Review

References (68)

1. Anand-Srivastava, M. B., Picard, S., and Thibault, C. (1991). Altered expression of inhibitory guanine nucleotide regulatory proteins (Gi alpha) in spontaneously hypertensive rats. Am.J.Hypertens.4, 840-843.
2. Aoki, J., Inoue, A., and Okudaira, S. (2008). Two pathways for lysophos-phatidic acid production. Biochem. Biophys. Acta 1781, 513-518.
3. Barth, M. C., Ahluwalia, N., Anderson, T. J., Hardy, G. J., Sinha, S., Alvarez-Cardona, J. A., Pruitt, I. E., Rhee, E. P., Colvin, R. A., and Gerszten, R. E. (2009). Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J. Biol. Chem. 284, 19189-19195.
4. Brown, A. J., Daniels, D. A., Kassim, M., Brown, S., Haslam, C. P., Ter-rell, V. R., Brown, J., Nichols, P. L., Staton, P. C., Wise, A., and Dowell, S. J. (2011). Pharmacology of GPR55 in yeast and identifica-tion of GSK494581A as a mixed-activity glycine transporter sub-type 1 inhibitor and GPR55 ago-nist. J. Pharmacol. Exp. Ther. 337, 236-246.
5. Bryan, B. A., Dennstedt, E., Mitchell, D. C., Walshe, T. E., Noma, K., Loureiro,R., Saint-Geniez,M.,Cam-paigniac, J. P., Liao, J. K., and D'Amore, P. A. (2010). RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angio-genesis. FASEB J. 24, 3186-3195.
6. Chen, Y., Meininger, V., and Guillemin, G. J. (2009). Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent. Nerv. Syst. Agents Med. Chem. 9, 32-39.
7. Connolly, J. O., Simpson, N., Hewlett, L., and Hall, A. (2002). Rac regu-lates endothelial morphogenesis and capillary assembly. Mol. Biol. Cell 13, 2474-2485.
8. Cosi,C.,Mannaioni,G.,Cozzi,A.,Carla, V., Sili, M., Cavone, L., Maratea, D., and Moroni, F. (2010). G-protein coupled receptor 35 (GPR35) acti-vation and inflammatory pain: Stud-ies on the antinociceptive effects of kynurenic acid and zaprinast. Neu-ropharmacology 60, 1227-1231.
9. Deng, H., Hu, H., and Fang, Y. (2011). Tyrphostin analogs are GPR35 ago-nists. FEBS Lett. 585, 1957-1962.
10. DeWire, S. M., Ahn, S., Lefkowitz, R. J., and Shenoy, S. K. (2007). Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510.
11. Dowell, S. J., and Brown, A. J. (2009). Yeast assays for G protein-coupled receptors. Methods Mol. Biol. 552, 213-229.
12. Fallarini, S., Magliulo, L., Paoletti, T., de Lalla, C., and Lombardi, G. (2010). Expression of functional GPR35 in human iNKT cells. Biochem. Bio-phys. Res. Commun. 398, 420-425.
13. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G., and Schioth, H. B. (2003). The G-protein-coupled receptors in the human genome form five main families. Phyloge-netic analysis,paralogon groups,and fingerprints. Mol. Pharmacol. 63, 1256-1272.
14. Gillessen, S., Naumov, Y. N., Nieuwen-huis, E. E., Exley, M. A., Lee, F. S., Mach, N., Luster, A. D., Blumberg, R. S., Taniguchi, M., Balk, S. P., Stro-minger, J. L., Dranoff, G., and Wil-son, S. B. (2003). CD1d-restricted T cells regulate dendritic cell func-tion and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fash-ion. Proc. Natl. Acad. Sci. U.S.A. 100, 8874-8879.
15. Guo, J., Williams, D. J., Puhl, H. L. III., and Ikeda, S. R. (2008). Inhibition of N-type calcium channels by activa-tion of GPR35, an orphan receptor, heterologously expressed in rat sym-pathetic neurons. J. Pharmacol. Exp. Ther. 324, 342-351.
16. Hamdan, F. F., Audet, M., Garneau, P., Pelletier, J., and Bouvier, M. (2005). High-throughput screening of G protein-coupled receptor antago-nists using a bioluminescence reso-nance energy transfer 1-based beta-arrestin2 recruitment assay. J. Bio-mol. Screen. 10, 463-475.
17. Heynen-Genel, S., Dahl, R., Shi, S., Sauer, M., Hariharan, S., Sergienko, E., Dad, S., Chung, T., Stonich, D., Su, Y., Caron, M., Abood, M. E., and Barak, L. S. (2010). Antago-nists for the Orphan Receptor GPR35. Probe Reports from the NIH Mol-ecular Libraries Program [Internet]. Bethesda, MD: National Center for Biotechnology Information.
18. Hilmas, C., Pereira, E. F., Alkondon, M., Rassoulpour, A., Schwarcz, R., and Albuquerque, E. X. (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increaes non-alpha7 nicotinic receptor expression: phys-iopathological implications. J. Neu-rosci. 21, 7463-7473.
19. Horikawa, Y., Oda, N., Cox, N. J., Li, X., Orho-Melander, M., Hara, M., Hinokio, Y., Lindner, T. H., Mashima, H., Schwarz, P. E., del Bosque-Plata, L., Horikawa, Y., Oda, Y., Yoshiuchi, I., Colilla, S., Polonsky, K. S.,Wei,S.,Concannon,P.,Iwasaki, N., Schulze, J., Baier, L. J., Bogar-dus, C., Groop, L., Boerwinkle, E., Hanis, C. L., and Bell, G. I. (2000). Genetic variation in the gene encod-ing calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 26, 163-175.
20. Imielinski, M., Baldassano, R. N., Grif-fiths, A., Russell, R. K., Annese, V., Dubinsky, M., Kugathasan, S., Brad-field, J. P., Walters, T. D., Sleiman, P., Kim, C. E., Muise, A., Wang, K., Glessner, J. T., Saeed, S., Zhang, H., Frackelton, E. C., Hou, C., Flory, J. H., Otieno, G., Chiavacci, R. M., Grundmeier, R., Castro, M., Latiano, A., Dallapiccola, B., Stempak, J., Abrams, D. J., Taylor, K., McGovern, D., Silber, G., Wrobel, I., Quiros, A., Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., Silverberg, M. S., Taylor, K. D., Barmuda, M. M., Bit-ton,A., Dassopoulos, T., Datta, L. W., Green, T., Griffiths, A. M., Kistner, E. O., Murtha, M. T., Regueiro, M. D., Rotter, J. I., Schumm, L. P., Stein-hartm,A. H., Targan, S. R., Xavier, R. J., Libioulle, C., Sandor, C., Lathrop, M., Belaiche, J., Dewit, O., Gut, I., Heath, S., Laukens, D., Mni, M., Rut-geerts, P., Van Gossum, A., Zelenika, D., Franchimont, D., Hugot, J. P., de Vos, M., Vermeire, S., Louis, E., Car-don, L. R., Anderson, C. A., Drum-mond, H., Nimmo, E., Ahmad, T., Prescott, N. J., Onnie, C. M., Fisher, S. A., Marchini, J., Ghori, J., Bump-stead, S., Gwillam, R., Tremelling, M., Delukas, P., Mansfield, J., Jew-ell, D., Satsangi, J., Mathew, C. G., Parkes, M., Georges, M., Daly, M. J., Heyman, M. B., Ferry, G. D., Kirschner,B.,Lee,J.,Essers,J.,Grand, R., Stephens, M., Levine, A., Piccoli, D., Van Limbergen, J., Cucchiara, S., Monos, D. S., Guthery, S. L., Den-son, L., Wilson, D. C., Grant, S. F., Daly, M., Silverberg, M. S., Satsangi, J.,and Hakonarson,H. (2009). Com-mon variants at five new loci associated with early-onset inflamma-tory bowel disease. Nat. Genet. 41, 1335-1340.
21. Jenkins, L., Alvarez-Curto, E., Camp-bell, K., de Munnik, S., Canals, M., Schlyer, S., and Milligan, G. (2011). Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha and beta-arrestin-2. Br. J. Pharmacol. 162, 733-748.
22. Jenkins, L., Brea, J., Smith, N. J., Hud-son, B. D., Reilly, G., Bryant, N. J., Castro, M., Loza, M. I., and Milligan, G. (2010). Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of beta-arrestin-2 and activate Gal-pha13. Biochem. J. 432, 451-459.
23. Kent, S. C., Chen, Y., Clemmings, S. M., Viglietta, V., Kenyon, N. S., Ricordi, C., Hering, B., and Hafler, D. A. (2005). Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J. Immunol. 175, 4458-4464.
24. Kostenis, E., Waelbroeck, M., and Mil-ligan, G. (2005). Promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26, 595-602.
25. Kuc, D., Zgrajka, W., Parada-Turska, J., Urbanik-Sypniewska, T., and Turski, W. A. (2008). Micromolar concen-tration of kynurenic acid in rat small intestine. Amino Acids 35, 503-505.
26. Lattin, J. E., Schroder, K., Su, A. I., Walker, J. R., Zhang, J., Wilt-shire, T., Saijo, K., Glass, C. K., Hume, D. A., Kellie, S., and Sweet, M. J. (2008). Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res. 4, 5.
27. Leonard, J. N., Chu, Z. L., Unett, D. J., Gatlin, J. E., Gaidarov, I., Qiu, J., Skinner, P. J., Boatman, D., Hume, S. A., Kellie, M. J., and Sweet Oat-man, P. D. (2007). GPR35 and mod-ulators thereof for the treatment of metabolic-related disorders. United States 20070077602.
28. Li, Y., and Anand-Srivastava, M. B. (2002). Inactivation of enhanced expression of G(i) proteins by per-tussis toxin attenuates the develop-ment of high blood pressure in spon-taneously hypertensive rats. Circ. Res. 91, 247-254.
29. Luttrell, L. M. (2003). 'Location, loca-tion, location': activation and tar-geting of MAP kinases by G protein-coupled receptors. J. Mol. Endocrinol. 30, 117-126.
30. Marchese, A., Paing, M. M., Temple, B. R., and Trejo, J. (2008). G Protein-Coupled Receptor Sorting to Endo-somes and Lysosomes. Annu. Rev. Pharmacol. Toxicol. 48, 601-629.
31. Maruyama, Y., Nishida, M., Sugimoto, Y., Tanabe, S., Turner, J. H., Kozasa, T., Wada, T., Nagao, T., and Kurose, H. (2002). Galpha(12/13) medi-ates alpha(1)-adrenergic receptor-induced cardiac hypertrophy. Circ. Res. 91, 961-969.
32. Milligan, G. (2003). Principles: extend-ing the utility of [35S]GTP gamma S binding assays. Trends Pharmacol. Sci. 24, 87-90.
33. Milligan, G. (2011). Orthologue selec-tivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol. Sci. 32, 317-325.
34. Milligan, G., and Kostenis, E. (2006). Hetero-trimeric G proteins: a short history. Br. J. Pharmacol. 147, S46- S55.
35. Mills, G. B., and Moolenaar, W. H. (2003). The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582-591.
36. Min, K. D., Asakura, M., Liao, Y., Nakamaru, K., Okazaki, H., Taka-hashi, T., Fujimoto, K., Ito, S., Taka-hashi, A., Asanuma, H.,Yamazaki, S., Minamino, T., Sanada, S., Seguchi, O., Nakano, A., Ando, Y., Otsuka, T., Furukawa, H., Isomura, T., Takashima, S., Mochizuki, N., and Kitakaze, M. (2010). Identification of genes related to heart failure using global gene expression profil-ing of human failing myocardium. Biochem. Biophys. Res. Commun. 393, 55-60.
37. Mizutani, K., Sugimoto, K., Okuda, T., Katsuya, T., Miyata, T., Tanabe, T., Higaki, J., Ogihara, T., Yamori, Y., Tsujita, Y., Tago, N., and Iwai, N. (2002). Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. Hypertens. Res. 25, 135-140.
38. Naumov, Y. N., Bahjat, K. S., Gausling, R., Abraham, R., Exley, M. A., Koezuka, Y., Balk, S. B., Strominger, J. L., Clare-Salzer, M., and B. Wil-son, S. (2001). Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. U.S.A. 98, 13838-13843.
39. Neubig, R. R. (2010). Mind your salts: when the inactive constituent isn't. Mol. Pharmacol. 78, 558-559.
40. Noguchi, K., Herr, D., Mutoh, T., and Chun, J. (2009). Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15-23.
41. O'Dowd, B. F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K. R., Heng, H. H., Kolakowski, L. F. Jr., and George, S. R. (1998). Discovery of three novel G-protein-coupled receptor genes. Genomics 47, 310-313.
42. Offermanns, S., Mancino, V., Revel, J. P., and Simon, M. I. (1997). Vas-cular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 275, 533-536.
43. Ohshiro, H., Tonai-Kachi, H., and Ichikawa, K. (2008). GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem. Biophys. Res. Commun. 365, 344-348.
44. Oka, S., Ota, R., Shima, M., Yamashita, A., and Sugiura, T. (2010). GPR35 is a novel lysophosphatidic acid recep-tor. Biochem. Biophys. Res. Commun. 395, 232-237.
45. Okumura, S., Baba, H., Kumada, T., Nanmoku, K., Nakajima, H., Nakane, Y., Hioki, K., and Ikenaka, K. (2004). Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci. 95, 131-135.
46. Patterson, A. D., Bonzo, J. A., Li, F., Krausz, K. W., Eichler, G. S., Aslam, S., Tigno, X., Weinstein, J. N., Hansen, B. C., Idle, J. R., and Gonzalez, F. J. (2011). Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J. Biol. Chem. 286, 19511-19522.
47. Pawlak, D., Tankiewicz, A., Mysliwiec, P., and Buczko, W. (2002). Trypto-phan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 90, 328-335.
48. Prescott, C., Weeks, A. M., Staley, K. J., and Partin, K. M. (2006). Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402, 108-112.
49. Renback, K., Inoue, M., and Ueda, H. (1999). Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve end-ings in mice. Neurosci. Lett. 270, 59-61.
50. Ruppel, K. M., Willison, D., Kataoka, H., Wang, A., Zheng, Y. W., Cor-nelissen, I., Yin, L., Xu, S. M., and Coughlin, S. R. (2005). Essential role for Galpha13 in endothelial cells during embryonic development. Proc. Natl. Acad. Sci. U.S.A. 102, 8281-8286.
51. Sharif, I., Crockett, T. R., Kane, K. A., and Wainwright, C. L. (2001). The effects of endothelin-1 on ischaemia-induced ventricular arrhythmias in rat isolated hearts. Eur. J. Pharmacol. 427, 235-242.
52. Shrimpton, A. E., Braddock, B. R., Thomson, L. L., Stein, C. K., and Hoo, J. J. (2004). Molecular delin-eation of deletions on 2q37.3 in three cases with an Albright heredi-tary osteodystrophy-like phenotype. Clin. Genet. 66, 537-544.
53. Smyth, S. S., Cheng, H. Y., Miriyala, S., Panchatcharam, M., and Morris, A. J. (2008). Roles of lysophospha-tidic acid in cardiovascular physiol-ogy and disease. Biochim. Biophys. Acta 1781, 563-570.
54. Sparfel, L., Pinel-Marie, M. L., Boize, M., Koscielny, S., Desmots, S., Pery, A., and Fardel, O. (2010). Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol. Sci. 114, 247-259.
55. Stone, T. W. (2001). Kynurenic acid antagonists and kynurenine path-way inhibitors. Expert Opin. Investig. Drugs 10, 633-645.
56. Sugiura, T., Nakane, S., Kishimoto, S., Waku, K., Yoshioka, Y., Tokumura, A., and Hanahan, D. J. (1999). Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochem. Biophys. Acta 1440, 194-204.
57. Sun, Y. V., Bielak, L. F., Peyser, P. A., Turner, S. T., Sheedy, P. F. II., Boerwinkle, E., and Kardia, S. L. (2008). Application of machine learning algorithms to predict coro-nary artery calcification with a sibship-based design. Genet. Epi-demiol. 32, 350-360.
58. Suzuki, N., Hajicek, N., and Kozasa, T. (2009). Regulation and physiolog-ical functions of G12/13-mediated signaling pathways. Neurosignals 17, 55-70.
59. Taniguchi, Y., Tonai-Kachi, H., and Shinjo, K. (2006). Zaprinast, a well-known cyclic guanosine monophosphate-specific phospho-diesterase inhibitor, is an agonist for GPR35. FEBS Lett. 580, 5003-5008.
60. Taniguchi, Y., Tonai-Kachi, H., and Shinjo, K. (2008). 5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist. Pharmacology 82, 245-249.
61. Tohgo, A., Choy, E. W., Gesty-Palmer, D., Pierce, K. L., Laporte, S., Oakley, R. H., Caron, M. G., Lefkowitz, R. J., and Luttell, L. M. (2003). The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional conse-quence of ERK activation. J. Biol. Chem. 278, 6258-6267.
62. Vassilatis, D. K., Hohmann, J. G., Zeng, H., Li, F., Ranchalis, J. E., Mortrud, M. T., Brown, A., Rodriguez, S. S., Weller, J. R., Wright, A. C., Bergmann, J. E., and Gaitanaris, G. A. (2003). The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. U.S.A. 100, 4903-4908.
63. Walczak, K. D., Browski, W., Langner, E., Zgrajka, W., Pi At, J., Kocki, T., Rzeski, W., and Turski, W. A. (2011). Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand. J. Gastroen-terol. 46, 903-912.
64. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., and Ling, L. (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281, 22021-22028.
65. Wilson, S. B., Kent, S. C., Patton, K. T., Orban, T., Jackson, R. A., Exley, M., Porcelli, S., Schatz, D. A., Atkin-son, M. A., Balk, S. P., Strominger, J. L., and Hafler, D. A. (1998). Extreme Th1 bias of invariant Val-pha24JalphaQ T cells in type 1 dia-betes. Nature 391, 177-181.
66. Yarur, A. J., Deshpande, A. R., Pechman, D. M., Tamariz, L., Abreu, M. T., and Sussman, D. A. (2011). Inflamma-tory Bowel Disease is associated with an increased incidence of cardiovas-cular events. Am. J. Gastroenterol. 106, 741-747.
67. Yoon, M. H., Choi, J., Bae, H. B., Kim, S. J., Chung, S. T., Jeong, S. W., Chung, S. S., Yoo, K. Y., and Jeong, C. Y. (2006). Antinociceptive effects and synergistic interaction with mor-phine of intrathecal metabotropic glutamate receptor 2/3 antagonist in the formalin test of rats. Neurosci. Lett. 394, 222-226.
68. Zhao, P., Sharir, H., Kapur, A., Cowan, A., Geller, E. B., Adler, M. W., H. Seltzman, H., Reggio, P. H., Heynen-Genel, S., Sauer, M., Chung, T. D., Bai, Y., Chen, W., Caron, M. G., Barak, L. S., and Abood, M. E. (2010). Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and beta-arrestin2 with antinociceptive activ-ity. Mol. Pharmacol. 78, 560-568.